Cargando…

Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer

5-Fluorouracil (5-FU) combined with radiotherapy is a common treatment strategy to treat human cancers, but the underlying mechanisms of this combination treatment remain unclear. Here, we report that NAD(+)-dependent deacetylase sirtuin-7 (SIRT7) protein levels were decreased due to 5-FU exposure r...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Ming, Lu, Xiaopeng, Zhang, Chaohua, Du, Changzheng, Cao, Linlin, Hou, Tianyun, Li, Zhiming, Tu, Bo, Cao, Ziyang, Li, Yinglu, Chen, Yongcan, Jiang, Lu, Wang, Hui, Wang, Lina, Liu, Baohua, Xu, Xingzhi, Luo, Jianyuan, Wang, Jiadong, Gu, Jin, Wang, Haiying, Zhu, Wei-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399598/
https://www.ncbi.nlm.nih.gov/pubmed/28435470
http://dx.doi.org/10.7150/thno.18804
Descripción
Sumario:5-Fluorouracil (5-FU) combined with radiotherapy is a common treatment strategy to treat human cancers, but the underlying mechanisms of this combination treatment remain unclear. Here, we report that NAD(+)-dependent deacetylase sirtuin-7 (SIRT7) protein levels were decreased due to 5-FU exposure rendering colorectal cancer cells sensitive to radiation. We found that SIRT7 downregulation was mediated via a Tat-binding Protein 1 (TBP1) proteasome-dependent pathway. Specifically, TBP1 was dephosphorylated at tyrosine 381 upon 5-FU treatment, which enhanced its direct interaction with SIRT7 and targeted it for degradation. Depletion of SIRT7 in cultured colorectal cancer cells induced radiosensitivity triggering cell death. Interestingly, decreased levels of SIRT7 mediated by 5-FU correlated well with improved therapeutic effect in patients with rectal cancer and with inhibited tumor growth in immune-compromised mice post-irradiation. Taken together, these data suggest that 5-FU induces radiosensitivity via SIRT7 degradation to favor a cell death pathway in targeted cancer cells. Thus, downregulation of SIRT7 could be a promising pharmacologic strategy to increase the effectiveness of chemoradiation therapy in cancer patients.